Neurologists in the U.S. expect — or, at least, highly anticipate — that Ocrevus (ocrelizumab), being developed by Roche as a treatment for both relapsing and progressive multiple sclerosis (MS), will be approved by year’s end, and a sizable number plan on quickly prescribing it, according to a recent update by Spherix Global Insights in “RealTime Dynamix: Multiple Sclerosis,” a quarterly report based on responses from over 100 neurologists actively treating MS patients.  Read on.

Proposed changes to the drug approval process mean NHS England will assess how much they can afford to pay for new drugs.

Under the plan, new drugs that are expected to cost the NHS more than £20 million a year would be subject to a ‘budget impact test’.  Read on.

From investigating if a stroke drug could repair damage caused in MS to testing the benefits of specialist rehab, these projects cover a wide range of topics.  Read on.

Stay well this Winter – make sure you get your flu jab.  For more information click here.

The experimental therapy laquinimod was seen to prevent the start of harmful immune responses and to disrupt the progression of multiple sclerosis (MS) in a mouse model of the disease. This finding may be especially promising, as the treatment is being developed for people with both relapsing MS and its rarer progressive form, for which no treatment currently exists.  Read on.

A drug that treats relapsing-remitting multiple sclerosis – a form of multiple sclerosis that accounts for around 85 percent of people with the condition – has been revealed to reverse some of the damage caused by the disease. This revelation may have implications for future therapeutic strategies for people with the neurological disease. Read on.

Disease modifying treatments (DMTs) may be able to reverse the symptoms caused by MS for some people with relapsing MS. This is according to new research published in the Journal of Neurology.  Read on.